login
Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

New renal impairment data from ROCKET AF study of rivaroxaban shows outcomes consistent with primary analysis


Tuesday, 30 Aug 2011 09:51



Findings from a key sub-analysis of the global phase III ROCKET AF study of patients with atrial fibrillation (AF) and moderate renal impairment demonstrate results in line with the study’s primary efficacy and safety analysis. 


The data presented at the European Society of Cardiology (ESC) by Keith Fox, co-chair of the ROCKET AF Executive Steering Committee and professor of Cardiology at the University of Edinburgh, show that these patients respond favourably to a reduced 15mg daily dose of Bayer’s Xarelto (rivaroxaban) compared with warfarin, an outcome consistent with those with preserved renal function who were given 20mg of rivaroxaban daily.


The use of traditional anticoagulants such as vitamin K antagonists (VKAs) including warfarin in patients with AF and renal impairment can be challenging for physicians, due to the need for regular dosing changes to avoid complications such as over-anticoagulation which can lead to major bleeding events. 

 

In this sub-group of 2,950 patients (representing 21% of the overall study population), rivaroxaban showed comparable safety outcomes to warfarin; importantly, rates of critical organ bleeding (HR 0.55; 95% CI 0.30-1.00) and fatal bleeding (HR 0.55; 95% CI 0.32-0.93) were lower with rivaroxaban, consistent with results seen by investigators in the ROCKET AF primary analysis. Gastrointestinal bleeding was more frequent in the rivaroxaban group compared to warfarin (4.1% vs. 2.6%, p=0.02). There were no significant differences in other bleeding sites between rivaroxaban 15mg and dose-adjusted warfarin.


The primary efficacy endpoint rate (incidence of stroke or non-central nervous systemic embolism) was 2.32 events per 100 patient years with rivaroxaban 15mg per day, compared with 2.77 events per 100 patient years with dose-adjusted warfarin  in the per-protocol population (HR 0.84; 95% CI 0.57-1.23, p value for interaction=0.76).


Together, these efficacy and safety findings confirm the primary results of ROCKET AF study published by the New England Journal of Medicine (NEJM) in August 2011.


The mean age of enrolled patients in ROCKET AF with moderate renal dysfunction was 79, older than the mean age of 73 in patients without renal dysfunction who received a higher 20mg dose of rivaroxaban.


“The findings of this analysis demonstrate that rivaroxaban has the ability to prevent stroke in patients with moderate renal insufficiency, without elevating the risk of critical bleeding events such as intra-cranial haemorrhage,” said Fox. “The average age of 79 in this group is also important, because patients with non-valvular AF tend to be of older age, and can have a higher risk of stroke due to the increased prevalence of conditions like congestive heart failure, hypertension, diabetes and prior stroke.”


Rivaroxaban is currently licensed in the UK for the prevention of venous thromboembolism (VTE) in patients undergoing elective total hip or knee replacement surgery, and is not licensed for the prevention of stroke and non-CNS systemic embolism in patients with non-valvular AF. 




Add New Comment

Related Items


Most popular


“We all need the strength” to challenge unacceptable behaviour
Thursday, 20 Aug 2015
The editors of Annals of Internal Medicine have called for doctors to confront colleagues who act in a disrespectful manner towards patients after an anonymous essay in the journal highlighted ... “We all need the strength” to challenge unacceptable behaviour

New stem cell delivery method shows promise for treating end stage heart failure
Monday, 27 Jul 2015
A new clinical trial to test how a high dose of stem cells delivered via a method called retrograde coronary sinus infusion affects end stage heart failure patients is showing promising results. New stem cell delivery method shows promise for treating end stage heart failure

First participants enrolled in dabigatran study of AF patients undergoing PCI
Wednesday, 29 Jul 2015
Boehringer Ingelheim has announced that the first US patients have been enrolled in its international clinical trial—RE-DUAL PCI, which is evaluating the efficacy and safety of dabigatran in patients ... First participants enrolled in dabigatran study of AF patients undergoing PCI

Features


New trial to explore oral anticoagulation benefit in patients with atrial high rate episodes
Monday, 03 Aug 2015
AFNET and the ESC are initiating a new trial (NOAH – AFNET 6) investigating whether patients without diagnosed atrial fibrillation who present with atrial high rate episodes benefit from oral ... New trial to explore oral anticoagulation benefit in patients with atrial high rate episodes

Safety, accuracy and validation of medical smartphone applications
Tuesday, 28 Jul 2015
The use of mobile smartphones and tablets that run applications (apps) to function as clinical examination tools, reference databases, technique guides, or medical calculators is today a reality in ... Safety, accuracy and validation of medical smartphone applications

Profiles


Cecilia Linde
Monday, 22 Jun 2015
Cecilia Linde speaks to Cardiac Rhythm News about her work on a research platform for new onset ... Cecilia Linde

Michael Gold
Wednesday, 03 Jun 2015
William Gold spoke to Cardiac Rhythm News about his involvement in various clinical trials, his ... Michael Gold

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions